Efficacy of Brigatinib in patients with nervous system tumors: A Systematic Review and Meta-Analysis
Caio Nazar Cunha1, Felipe Gouhie1, Gabriel Carísio1, Ricardo Filho1, João Alves Rodrigues1, Larissa Ferreira Machado1, Lucas Figueira Vieira1, Pedro Borges1, Victor Luiz Furlan1, Jose Neto1, Hélio Queiroz1
1University of Uberlandia
Objective:
Carry out a meta-analysis to assess the efficacy and safety of Brigatinib regarding the treatment of nervous system tumors, especially related to tumoral response.
Background:
Brigatinib is a targeted cancer therapy that belongs to a class of drugs known as tyrosine kinase inhibitors, effective in the treatment of non-small cell lung cancer with a specific genetic alteration known as anaplastic lymphoma kinase fusion. However, there is still no consolidated evidence regarding the efficacy and safety of Brigatinib in treating central nervous system (CNS) tumors.
Design/Methods:
A comprehensive systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was conducted to evaluate the use of Brigatinib in patients with nervous system tumors. The search was conducted using the following databases: PubMed, Embase, and Cochrane. Statistical analysis was performed using R Studio software, version 4.3.1, and will include a comparison of the effects of Brigatinib on efficacy and safety. Study heterogeneity was assessed using the I² index.
Results:
Eleven interventional studies were included in the analysis, comprising 1016 patients. In these articles, the response rate with Brigatinib in patients with a nervous system tumor was 56.94% (95% CI 48.03 to 65.67%).
Conclusions:
This study shows a moderate overall response rate across the included studies, with significant heterogeneity, suggesting considerable variability. Despite this, the response rates indicate Brigatinib's potential efficacy in treating CNS tumors.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.